← Oncology Approval Tracker

FDA DECISION ·

Imbruvica + rituximab

ibrutinib + rituximab · Pharmacyclics

FDA approvalNew or expanded indicationChronic lymphocytic leukemia and small lymphocytic lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults receiving initial treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma.

LAMPGEN ANALYSIS

Why it matters

Added a BTK inhibitor plus anti-CD20 regimen for first-line care.

What research teams should watch

Coordinate oral adherence monitoring with infusion visits and verify bleeding-risk medications.

PRIMARY RECORDS

Sources